AIM ImmunoTech Inc.
AIM evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $8.3M
- Lead Asset:
- alferon n (Approved)
What it means
What to watch
Prepared research question
What matters most for AIM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIM
AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company developing its lead drug Ampligen® (rintatolimod), a TLR3 agonist, primarily for pancreatic cancer, with a Phase 2 DURIPANC study underway and a cash position of $9.9M as of 2026-06-30 [sec].
Key risk: Insufficient funding
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 9 clinical trials · 1 catalyst for AIM ImmunoTech Inc..
AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company developing its lead drug Ampligen® (rintatolimod), a TLR3 agonist, primarily for pancreatic cancer, with a Phase 2 DURIPANC study underway and a cash position of $9.9M as of 2026-06-30 [sec].
- Lead drug Ampligen® (rintatolimod) is a selective Toll-like Receptor 3 (TLR3) agonist being evaluated in a Phase 2 DURIPANC study for late-stage pancreatic cancer in combination with AstraZeneca’s Imfinzi® (durvalumab) [pipeline].
- Cash & equivalents were $9.9M as of 2026-06-30, with total revenue of $0.0M and net income of -$3.8M for the period [sec].
- Accumulated deficit was approximately $440,786,000 as of December 31, 2025 [sec_mda].
- The company executed a 1-for-100 reverse stock split and regained compliance with the Exchange on June 17, 2025 after a low-selling-price suspension [sec_mda].
- A primary endpoint analysis for the DURIPANC study is expected in December 2026 [news · 2026-06-24].
What works
- Ampligen in combination with durvalumab showed promising signs of no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) in a mid-2025 report [news · 2025-08-15].
- The company has a focused strategy on pancreatic cancer with a defined Phase 2 DURIPANC study and a planned Phase 2 start for locally advanced pancreatic adenocarcinoma on 2027-08-01 [catalyst].
- AIM has an FDA-approved drug (Alferon N Injection) and is actively seeking senior co-development partners to commercialize its experimental drugs [sec_mda].
What to weigh
- The company has not yet generated revenue from product sales and reported $0.0M total revenue as of 2026-06-30 [sec].
- Accumulated deficit was approximately $440,786,000 as of December 31, 2025, indicating a long history of losses [sec_mda].
- Management states that current funds may not be adequate to meet anticipated operational cash needs and fund current clinical trials, requiring additional funding [sec_mda].
- The company was suspended from trading on the Exchange due to low selling price and only regained compliance in June 2025, reflecting financial and operational stress [sec_mda].
From the filings
Quoted directly from source documents.
Ampligen is a TLR3 agonist in Phase 2 for pancreatic cancer
“selective Toll-like Receptor 3 ("TLR3") agonist”
Accumulated deficit as of December 31, 2025
“accumulated deficit was approximately $440,786,000”
SEC MD&A · March 27, 2026
DURIPANC primary endpoint analysis expected December 2026
“DURIPANC Primary Endpoint Analysis Expected In December 2026”
News · June 24, 2026
Catalyst timeline
- 2027-08-01 · Phase2_Start: A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma — This is the planned start of a new Phase 2 study for Ampligen in locally advanced pancreatic adenocarcinoma, which will test the drug in combination with standard of care.
Risks & what to watch (4)›
Key risks
- Insufficient funding — Management states current funds may not be adequate for operational needs and clinical trials; additional funding required [sec_mda].
- No product revenue — Total revenue was $0.0M as of 2026-06-30; company has not yet generated revenue from product sales [sec].
- Large accumulated deficit — Accumulated deficit of ~$440.8M as of Dec 31, 2025, reflecting sustained losses [sec_mda].
- Clinical trial risk — Phase 2 DURIPANC study may not yield positive results, requiring unanticipated changes or additional studies [sec_mda].
What to watch
- DURIPANC primary endpoint analysis expected in December 2026 [news · 2026-06-24].
- Phase 2 start for locally advanced pancreatic adenocarcinoma on 2027-08-01 [catalyst].
- Ability to secure co-development partners and additional funding to sustain operations [sec_mda].
- Any updates on Ampligen’s potential for Ebola virus treatment, with pre-clinical data presentation announced [news · 2026-05-27].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run AIM ImmunoTech Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AIM ImmunoTech Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.64 · 0% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~292d
4 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 3.1%
- Days to cover
- 0.0
- Shares short
- 248,631
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIM short interestGovernance
Frequently asked questions
What is the AI investment thesis for AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is a clinical-stage immuno-pharma company developing its lead drug Ampligen® (rintatolimod), a TLR3 agonist, primarily for pancreatic cancer, with a Phase 2 DURIPANC study underway and a cash position of $9.9M as of 2026-06-30 [sec].
What is AIM ImmunoTech Inc.'s lead drug candidate?
AIM ImmunoTech Inc.'s most advanced tracked candidate is alferon n (Approved) for refractory or recurring external genital warts.
What is AIM ImmunoTech Inc.'s next catalyst?
AIM ImmunoTech Inc.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma" — expected August 1, 2027.
Who is the CEO of AIM ImmunoTech Inc.?
Mr. Thomas K. Equels Esq., J.D., M.S. is the chief executive officer of AIM ImmunoTech Inc. (AIM).
Where is AIM ImmunoTech Inc. headquartered?
AIM ImmunoTech Inc. (AIM) is headquartered in Ocala, FL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.